MaaT Pharma SA (MAAT.PA)
EUR 8.1
(1.0%)
EUR 8.1
(1.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 14.07 Million EUR | 23.88% |
| 2022 | 11.36 Million EUR | 95.69% |
| 2021 | 5.8 Million EUR | -4.44% |
| 2020 | 6.07 Million EUR | -41.94% |
| 2019 | 10.46 Million EUR | 302.19% |
| 2018 | 2.6 Million EUR | 50.93% |
| 2017 | 1.72 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 11.52 Million EUR | 49.05% |
| 2024 Q1 | 11.52 Million EUR | -18.15% |
| 2023 FY | 14.07 Million EUR | 23.88% |
| 2023 Q1 | 12.97 Million EUR | 14.18% |
| 2023 Q4 | 14.07 Million EUR | 9.59% |
| 2023 Q3 | 12.84 Million EUR | -1.01% |
| 2023 Q2 | 12.97 Million EUR | 0.01% |
| 2022 Q4 | 11.36 Million EUR | 1.91% |
| 2022 Q3 | 11.14 Million EUR | 34.5% |
| 2022 Q2 | 8.28 Million EUR | 2.38% |
| 2022 Q1 | 8.09 Million EUR | 39.44% |
| 2022 FY | 11.36 Million EUR | 95.69% |
| 2021 Q1 | 5.82 Million EUR | -4.16% |
| 2021 FY | 5.8 Million EUR | -4.44% |
| 2021 Q4 | 5.8 Million EUR | 3.46% |
| 2021 Q3 | 5.61 Million EUR | -5.22% |
| 2021 Q2 | 5.92 Million EUR | 1.68% |
| 2020 Q4 | 6.07 Million EUR | 1.38% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q3 | 5.99 Million EUR | 0.0% |
| 2020 FY | 6.07 Million EUR | -41.94% |
| 2019 FY | 10.46 Million EUR | 302.19% |
| 2018 FY | 2.6 Million EUR | 50.93% |
| 2017 FY | 1.72 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -315.192% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 74.623% |
| Adocia SA | 13.08 Million EUR | -7.541% |
| Aelis Farma SA | 4.03 Million EUR | -248.564% |
| Biophytis S.A. | 8.27 Million EUR | -70.193% |
| Advicenne S.A. | 17.42 Million EUR | 19.225% |
| genOway Société anonyme | 7.23 Million EUR | -94.583% |
| IntegraGen SA | 1.12 Million EUR | -1151.406% |
| Medesis Pharma S.A. | 1.2 Million EUR | -1072.917% |
| Neovacs S.A. | 650 Thousand EUR | -2065.385% |
| NFL Biosciences SA | 62.17 Thousand EUR | -22538.08% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -223.08% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -418.065% |
| Sensorion SA | 2.86 Million EUR | -390.625% |
| Theranexus Société Anonyme | 3.64 Million EUR | -286.355% |
| TME Pharma N.V. | 1.16 Million EUR | -1107.118% |
| Valbiotis SA | 6.87 Million EUR | -104.638% |
| TheraVet SA | 1.15 Million EUR | -1113.501% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -56.424% |
| argenx SE | 18.1 Million EUR | 22.26% |
| BioSenic S.A. | 28.16 Million EUR | 50.02% |
| Celyad Oncology SA | 902 Thousand EUR | -1460.421% |
| DBV Technologies S.A. | 13.01 Million USD | -8.115% |
| Galapagos NV | 9.59 Million EUR | -46.676% |
| Genfit S.A. | 70.17 Million EUR | 79.944% |
| GeNeuro SA | 7.73 Million EUR | -81.899% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -165.867% |
| Innate Pharma S.A. | 39.89 Million EUR | 64.718% |
| Inventiva S.A. | 37.4 Million EUR | 62.373% |
| MedinCell S.A. | 58.96 Million EUR | 76.128% |
| Nanobiotix S.A. | 50.56 Million EUR | 72.165% |
| Onward Medical N.V. | 16.87 Million EUR | 16.588% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -2.833% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 69.269% |
| Oxurion NV | 12.33 Million EUR | -14.115% |
| Pharming Group N.V. | 155.29 Million EUR | 90.937% |
| Poxel S.A. | 46.9 Million EUR | 69.989% |
| GenSight Biologics S.A. | 18.42 Million EUR | 23.622% |
| Transgene SA | 1.25 Million EUR | -1019.73% |
| Financière de Tubize SA | 79.2 Million EUR | 82.229% |
| UCB SA | 3.03 Billion EUR | 99.537% |
| Valneva SE | 208.81 Million EUR | 93.26% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -36939.474% |